Unidade de Ciências Químicas e Radiofarmacêuticas, ITN, Estrada Nacional 10, 2686-953 Sacavém, Portugal.
Eur J Med Chem. 2012 Apr;50:350-60. doi: 10.1016/j.ejmech.2012.02.014. Epub 2012 Feb 14.
The (99m)Tc (I) tricarbonyl complexes fac-[(99m)Tc(κ(3)-L)(CO)(3)] (Tc1-Tc6) containing N-ethylpyrrolidine and N,N-diethylethylamine groups for melanin binding, were evaluated in vitro and in vivo as radioactive probes for the targeting of melanotic melanoma. Aiming at the modification of their size, topology and lipophilicity, Tc1-Tc6 were obtained based on an S,N,O-donor bifunctional chelator (BFC) derived from cysteamine and on pyridyl- and pyrazolyl-containing N,N,O-donor BFCs. Tc1-Tc6 were chemically identified by HPLC comparison with the Re congeners (Re1-Re6) that were synthesized at the macroscopic level and fully characterized by common analytical techniques. With the exception of Tc5 and Tc6, these (99m)Tc complexes are moderately lipophilic, and bind to melanin with moderate to high affinity (23-87%). The cell uptake of Tc1-Tc6, expressed as a percentage of total activity per million cells, spanned between 0.86 and 21.02% for the melanotic B16-F1 cell line and between 0.49% and 13.58% for the amelanotic A375 cell line. In the B16-F1 cell line, Tc1, Tc3 and Tc4 showed moderate cellular uptake values (>10% at 4 h of incubation). In the amelanotic A375 cell line, only Tc4 has shown a moderate cell uptake (>10% at 4 h of incubation), with all the other compounds displaying a relatively poor uptake, i.e. inferior to 5%. Competition studies with haloperidol have shown that the involvement of sigma receptors in cellular uptake and retention is likely to occur for Tc4. Complex Tc1, stabilized with the S,N,O-donor BFC and containing a N,N-diethylethylamine group, presented the most promising biological profile for in vivo targeting of melanoma, showing a moderate tumor uptake of 2.17% ID/g at 1 h p.i in a B16-F1 melanoma-bearing mouse and rather favorable target/non-target ratios with values as high as 16.9 and 5.2 for tumor/muscle and tumor/blood ratios, respectively.
研究了含有 N-乙基吡咯烷和 N,N-二乙乙基胺基团的(99m)Tc(I)三羰基配合物 fac-[(99m)Tc(κ(3)-L)(CO)(3)](Tc1-Tc6)作为黑色素结合物的黑色素瘤靶向放射性探针的体外和体内性质。为了修饰其大小、拓扑结构和亲脂性,Tc1-Tc6 是基于半胱氨酸衍生的 S,N,O-供体双功能螯合剂(BFC)和含吡啶基和吡唑基的 N,N,O-供体 BFC 合成的。Tc1-Tc6 通过与宏观水平合成并通过常见分析技术充分表征的 Re 同系物(Re1-Re6)的 HPLC 比较进行了化学鉴定。除了 Tc5 和 Tc6 之外,这些(99m)Tc 配合物具有中等亲脂性,与黑色素具有中等至高亲和力(23-87%)结合。Tc1-Tc6 的细胞摄取率表示为每百万个细胞的总放射性活度的百分比,对于黑色素瘤 B16-F1 细胞系,在 0.86%和 21.02%之间,对于无黑色素瘤 A375 细胞系,在 0.49%和 13.58%之间。在 B16-F1 细胞系中,Tc1、Tc3 和 Tc4 显示出中等的细胞摄取率(在 4 小时孵育时>10%)。在无黑色素瘤 A375 细胞系中,只有 Tc4 显示出中等的细胞摄取率(在 4 小时孵育时>10%),而其他所有化合物的摄取率相对较低,即低于 5%。用氟哌啶醇进行的竞争研究表明,sigma 受体参与细胞摄取和保留可能发生在 Tc4 中。用 S,N,O-供体 BFC 稳定并含有 N,N-二乙乙基胺基团的 Tc1 复合物表现出最有前途的体内黑色素瘤靶向生物特征,在携带 B16-F1 黑色素瘤的小鼠中,在 1 小时时肿瘤摄取率为 2.17%ID/g,并且具有相当有利的靶/非靶比,高达 16.9 和 5.2 用于肿瘤/肌肉和肿瘤/血液比值。